6月1日，阿斯利康盘中下跌3.03%，报180.16美元/股，成交额8859.88万美元。
消息面上，公司旗下Alexion罕见病部门近日披露，评估anselamimab治疗轻链淀粉样变性的CARES III期临床项目在总体患者人群中未达到主要终点。尽管预设Kappa亚组显示全因死亡率改善62%、心血管住院率降低71%，但整体数据未能达标，构成管线层面利空。
此外，制药行业当日普遍走弱，礼来跌2.16%、强生跌1.54%、辉瑞跌2.5%、默沙东跌2.97%、施贵宝跌3.67%，板块联动效应加剧公司股价下行压力。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.